ClinicalTrials.gg
CompletedNCT05192395Updated Jul 11, 2022

A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers

A Phase 1 interventional study of DWJ1525 and DWP16001 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-11.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Four-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of DWJ1525 and the Co-administration of DWP16001 and DWC202101 for Healthy Subjects in Fed and Fasted State

Read the detailed description

A single dose of the test (T) and two of the reference (R) products will be administered to the study subjects, according to a randomized, open-label, single oral dosing, two-sequence, and four-period crossover for healthy subjects in fed and fasted state study design.

A wash-out interval of at least 7 days will elapse between the each administrations.

The three investigational products will be administered with 150 mL of still mineral water on day 1 of the four study periods.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Before participating in the clinical trial, a person who fully explained the purpose, content, and characteristics of the clinical trial drug and signed a written consent form approved by the IRB of Bundang Cha Hospital to participate in this study according to his free will.
  2. Healthy adults aged 19 or older at the time of screening.
  3. Those who weigh more than 50 kg in men, weigh more than 45 kg in women, and have a (BMI) of 18.0 kg/m2 or more and less than 30.0 kg/m2 or less in women.

    • Body mass index (BMI) = Weight (kg) / [Height (m)] 2.

Exclusion criteria

Exclusion Criteria:

  1. A person with a history in liver, kidney, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, blood and tumor system, cardiovascular system (including orthostatic hypotension), etc.
  2. A history of gastrointestinal diseases (e.g., esophageal diseases such as Crohn's disease, esophageal achalasia, or esophageal stenosis) or surgery (except appendectomy, hernia, endoscopic polyp surgery, hemorrhoids, hemorrhoids, hemorrhoids, and healing surgery).
  3. Those who are hypersensitive to other drugs (aspirin, antibiotics, etc.) or have a history of clinically significant reactions, including clinical drug ingredients (Enavogliflozin, Metformin) and homogeneous (SGLT2 inhibitors)
  4. A person who shows the following results in the inspection items conducted during screening.

    • Blood , AST, Total > twice the
    • The (e-GFR) \<90 mL/min/1.73 m2 (using the CKD-EPI method)
    • If the blood glucose level is greater than 125 mg/dL or less than 60 mg/dL,
    • After more than 3 minutes of rest, systolic blood pressure > 150 mmHg or \<90 mmHg, or diastolic blood pressure > 100 mmHg or \<50 mmHg in vital signs measured at the seat.
  5. A person whose abnormal results were judged to be clinically significant in screening test items (examination, vital signs, , physical examination, blood, urinary examination, etc.) other than those mentioned in paragraph 4).
  6. Drugs that do not affect the safety and research results of the subject may be available within 14 days of the first administration of clinical trial drugs (including herbal medicines), general medicines (including vitamins), and health functional foods.)
  7. Those who took other clinical trial drugs within 180 days before the first scheduled date of administration of clinical trial drugs (however, the criteria for termination of participation in previous clinical trials are calculated as one day based on the last administration date.)
  8. A person who has continuously consumed more than 21 units/week (1 unit = 10g = 12.5 mL) within 6 months of screening or cannot abstain from drinking alcohol from 3 days before the first administration of clinical trial drugs to the last visit.

    ☞ Alcohol amount (g) = Consumption (mL) x frequency (%) x 0.8

  9. Those who smoke more than 10 cigarettes a day within 6 months of screening and who cannot quit smoking excessively from 3 days before the first clinical trial drug administration to the last visit or quit smoking from the date of hospitalization to the last blood collection.
  10. A person who donated whole blood within 8 weeks before the first scheduled date of administration of clinical trial drugs, or who donated whole blood within 4 weeks (plasma, ), or did not agree to prohibit blood donation until 30 days after the last administration date.
  11. Those who did not agree to stop taking diet (e.g., grapefruit) that could affect the absorption, distribution, metabolism, and excretion of drugs from three days before the first administration of clinical trial drugs to the last blood collection.
  12. Those who do not agree to consume excessive caffeine (400 mg/day) from 3 days before the first clinical trial drug administration to the last visit or to stop consuming caffeine-containing foods from the date of hospitalization to the time of blood collection.
  13. A person who does not use the appropriate method recognized by his/her spouse or partner from the time of written consent to the subject until two weeks after the date of administration of the last clinical trial drug.
  14. Pregnant women or lactating women identified during screening.
  15. Other persons who have judged that they are inappropriate to participate in this examination as judged by the tester.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Group A

    fed state: period 1) DWJ15251, period 2) DWP16001 and DWC2021011 fased state: period 3) DWJ15251, period 4) DWP16001 and DWC2021011

    Drug: DWJ1525 · Drug: DWP16001 · Drug: DWC202101

  • Experimental
    Group B

    fed state: period 1) DWP16001 and DWC2021011, period 2) DWJ15251 fased state: period 3) DWP16001 and DWC2021011, period 4) DWJ15251

    Drug: DWJ1525 · Drug: DWP16001 · Drug: DWC202101

Interventions

  • DrugDWJ1525

    DWJ1525

  • DWP16001

  • DrugDWC202101

    DWC202101

06

What researchers measure

Primary outcomes

  1. AUClast

    AUClast of plasma DWP16001 and DWC202101

    Time frame: At pre-dose (0) and 0.25 to 72 hours post dose

  2. Cmax

    Cmax of plasma DWP16001 and DWC202101

    Time frame: At pre-dose (0) and 0.25 to 72 hours post dose

07

Study locations

1 site
  • CHA unuversity bundang medical center
    Seongnam, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 14, 2022
StartActual
Apr 15, 2022
Primary completionActual
May 24, 2022
CompletionActual
May 24, 2022
Last update
Jul 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05192395
Responsible party
Sponsor
First posted
Jan 14, 2022
Start date
Apr 15, 2022
Primary completion
May 24, 2022
Completion
May 24, 2022
Last update
Jul 11, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion